X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anti-ctla4 (63) 63
index medicus (54) 54
humans (53) 53
immunotherapy (52) 52
melanoma (49) 49
oncology (45) 45
ipilimumab (39) 39
metastatic melanoma (34) 34
anti-pd1 (33) 33
anti-ctla4 antibody (22) 22
cancer (22) 22
melanoma - drug therapy (20) 20
nivolumab (19) 19
antibodies, monoclonal - therapeutic use (18) 18
male (18) 18
immunology (16) 16
antibodies, monoclonal - adverse effects (15) 15
female (15) 15
middle aged (14) 14
skin neoplasms - drug therapy (14) 14
pembrolizumab (13) 13
aged (12) 12
metastasis (12) 12
open-label (12) 12
anti-pd-1 (11) 11
ctla-4 antigen - antagonists & inhibitors (11) 11
ctla-4 antigen - immunology (11) 11
immune checkpoint inhibitors (11) 11
therapy (11) 11
animals (10) 10
antibodies (10) 10
care and treatment (10) 10
dermatology (10) 10
medicine & public health (10) 10
survival (10) 10
aged, 80 and over (9) 9
chemotherapy (9) 9
ctla-4 protein (9) 9
adult (8) 8
antineoplastic agents - therapeutic use (8) 8
colitis (8) 8
combination (8) 8
immune checkpoint (8) 8
melanoma - pathology (8) 8
neoplasms - immunology (8) 8
tremelimumab (8) 8
adverse events (7) 7
antibodies, monoclonal - administration & dosage (7) 7
antineoplastic agents - adverse effects (7) 7
blockade (7) 7
clinical trials (7) 7
ctla-4 blockade (7) 7
double-blind (7) 7
melanoma - immunology (7) 7
melanoma - therapy (7) 7
monoclonal antibodies (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
analysis (6) 6
anti-pd-l1 (6) 6
clinical trials as topic (6) 6
combination immunotherapy (6) 6
cytotoxicity (6) 6
immunotherapy - methods (6) 6
lymphocytes (6) 6
medicine, research & experimental (6) 6
melanoma - secondary (6) 6
metastases (6) 6
mice (6) 6
phase-ii (6) 6
phase-ii trial (6) 6
programmed cell death 1 receptor - immunology (6) 6
prostate-cancer (6) 6
skin neoplasms - pathology (6) 6
trial (6) 6
anti-pdl1 (5) 5
antibodies, monoclonal - immunology (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
article (5) 5
braf inhibitor (5) 5
checkpoint inhibitors (5) 5
ctla-4 (5) 5
dendritic cells (5) 5
drug therapy (5) 5
hepatitis (5) 5
immunologic factors - adverse effects (5) 5
immunotherapy - adverse effects (5) 5
in-vivo (5) 5
monoclonal-antibody (5) 5
neoplasms - drug therapy (5) 5
regulatory t-cells (5) 5
safety (5) 5
sarcoidosis (5) 5
t cells (5) 5
t-cells (5) 5
t-lymphocytes - immunology (5) 5
treatment outcome (5) 5
tumors (5) 5
antigens (4) 4
antigens, cd - immunology (4) 4
antineoplastic agents, immunological - adverse effects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hematology and Oncology, 04/2017, Volume 10, Issue 1
Journal Article
Revue Neurologique, ISSN 0035-3787, 04/2018, Volume 174, pp. S57 - S58
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2019, Volume 119, pp. 122 - 131
Age-related immune dysfunction (ARID) describes age-associated changes in immunity that may affect the efficacy of immunotherapy with checkpoint inhibitors. We... 
Pembrolizumab | Ipilimumab | Anti-CTLA4 | Malignant melanoma | Antibodies | Monoclonal | Anti-PD1 | Survival | Age | Index Medicus
Journal Article
EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, 03/2017, Volume 73, pp. 1 - 8
Immune checkpoint inhibitors (ICIs) targeting CTLA4 and PD1 constitute a promising class of cancer treatment but are associated with several immune-related... 
Anti-CTLA4 | Neurological adverse events | GUILLAIN-BARRE-SYNDROME | Immune checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | CELL LUNG-CANCER | PHASE-II TRIAL | ONCOLOGY | LONG-TERM SAFETY | PRETREATED ADVANCED MELANOMA | Anti-PD1 | RESISTANT PROSTATE-CANCER | CTLA4 BLOCKADE | IPILIMUMAB TREATMENT
Journal Article
Actas Dermo-Sifiliograficas, ISSN 0001-7310, 10/2017, Volume 108, Issue 8, pp. 721 - 728
Metastatic or locally advanced unresectable melanoma carries a high morbidity and mortality. However, notable advances have been made in recent years in the... 
Antibodies | Anti-PD1 | Immunomodulators | Anti-CTLA4 | Melanoma
Journal Article
Actas Dermo-Sifiliograficas, ISSN 0001-7310, 10/2017, Volume 108, Issue 8, pp. 721 - 728
Metastatic or locally advanced unresectable melanoma carries a high morbidity and mortality. However, notable advances have been made in recent years in the... 
Anti-CTLA4 | Melanoma | Antibodies | Anti-PD1 | Immunomodulators
Journal Article
Progres en Urologie, ISSN 1166-7087, 03/2018, Volume 28, Issue 3, pp. 137 - 145
Context: Nivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line... 
Anti-PDL1 | Renal cell carcinoma | Anti-CTLA4 | Immunotherapy | Anti-PD1
Journal Article
Actas Dermo-Sifiliográficas (English Edition), ISSN 1578-2190, 10/2017, Volume 108, Issue 8, pp. 721 - 728
Metastatic or locally advanced unresectable melanoma carries a high morbidity and mortality. However, notable advances have been made in recent years in the... 
Anticuerpos | Anti-CTLA4 | Melanoma | Antibodies | Anti-PD1 | Inmunomoduladores | Immunomodulators
Journal Article
Actas Dermo-Sifiliográficas, ISSN 0001-7310, 2017, Volume 108, Issue 8, pp. 721 - 728
Resumen El melanoma irresecable localmente avanzado y metastásico es una situación clínica asociada a una elevada tasa de morbimortalidad. En los últimos años,... 
Dermatology
Journal Article
Actas Dermo-Sifiliograficas, ISSN 0001-7310, 01/2019, Volume 110, Issue 1, pp. 43 - 49
Granulomatous sarcoidosis-like reactions affecting multiple organ systems at one time have infrequently been described within weeks to months after initiation... 
Metastatic melanoma | Sarcoidosis | Granulomatous reaction | Anti-CTLA4 | Immunotherapy | Adverse drug reaction | Immune-related adverse event
Journal Article
Journal Article
Progres en Urologie, ISSN 1166-7087, 03/2018, Volume 28, Issue 3, pp. 137 - 145
En 2015, le nivolumab, un inhibiteur du point de contrôle immunitaire ciblant les récepteurs PD1 a été le premier traitement qui a amélioré la survie globale... 
Anti-PDL1 | Renal cell carcinoma | Anti-CTLA4 | Immunotherapy | Cancer du rein | Anti-PD1 | Immunothérapie
Journal Article
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, pp. 548 - 550
Journal Article
Journal Article
Tohoku Journal of Experimental Medicine, ISSN 0040-8727, 2019, Volume 248, Issue 1, pp. 37 - 43
Journal Article
Hepato-Gastro and Oncologie Digestive, ISSN 2115-3310, 12/2016, Volume 23, Issue 10, pp. 966 - 974
Journal Article
Journal of immunotherapy (Hagerstown, Md. : 1997), ISSN 1524-9557, 11/2012, Volume 35, Issue 9, pp. 702 - 710
Changes in the biomarkers of host suppressor immune response were evaluated in patients with melanoma enrolled on two trials. Two similar cohorts of patients... 
anti-CTLA4 | melanoma | T-regulatory cells | MDSC | interferon-α
Journal Article
JOURNAL OF IMMUNOTHERAPY, ISSN 1524-9557, 11/2012, Volume 35, Issue 9, pp. 702 - 710
Changes in the biomarkers of host suppressor immune response were evaluated in patients with melanoma enrolled in 2 trials. Two similar cohorts of patients... 
MEDICINE, RESEARCH & EXPERIMENTAL | CTLA-4 BLOCKADE | MDSC | COLONY-STIMULATING FACTOR | melanoma | IMMUNOLOGY | ADJUVANT | anti-CTLA4 | RESPONSES | PHASE-II TRIAL | CANCER-PATIENTS | THERAPY | interferon-a | ONCOLOGY | T regulatory cells | IMMUNE SUPPRESSION | CUTANEOUS MELANOMA | TUMOR MICROENVIRONMENT
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.